Learn more →
Back to Expert Scholars
medical-oncology / medical-oncologyMelanoma

Ulrich Keilholz

乌尔里希·凯尔霍尔茨

MD

🏢Charité – Universitätsmedizin Berlin(柏林夏里特大学医院)🌐Germany

Director of the Comprehensive Cancer Center Charité (CCCC)夏里特综合癌症中心主任

56
h-index
3
Key Papers
4
Awards
3
Key Contributions

👥Biography 个人简介

Professor Ulrich Keilholz directs the Charité Comprehensive Cancer Center in Berlin and is a leading European expert in melanoma and head and neck cancers. He has made major contributions to immunotherapy, T-cell therapy for melanoma, and cetuximab combinations in head and neck squamous cell carcinoma.

Share:

🧪Research Fields 研究领域

Melanoma黑色素瘤
Head and Neck Cancer头颈部肿瘤
Immunotherapy免疫治疗
T-Cell TherapyT细胞疗法

🎓Key Contributions 主要贡献

Melanoma Immunotherapy

Conducted landmark early trials of interleukin-based immunotherapy and later checkpoint inhibitors in melanoma, helping define predictive markers and combination approaches for durable response.

Head and Neck Squamous Cell Carcinoma

Contributed to EXTREME and TPEx trial data supporting platinum-cetuximab regimens, and led translational work on HPV status and immune contexture in HNSCC prognosis.

Cancer Center Leadership

Built the CCCC into a nationally designated comprehensive cancer center integrating tumor boards, precision diagnostics, and early-phase trials, serving as a model for German oncology.

Representative Works 代表性著作

[1]

Ipilimumab in advanced melanoma: long-term survival analysis

Journal of Clinical Oncology (2014)

Pooled analysis confirming durable long-term survival plateau with ipilimumab, establishing the curative potential of CTLA-4 blockade in advanced melanoma.

[2]

Dacarbazine versus dacarbazine plus interferon in advanced melanoma

Journal of Clinical Oncology (2002)

Established evidence base for systemic therapy in pre-immunotherapy era melanoma, providing benchmark survival data referenced in subsequent immunotherapy trials.

[3]

Cetuximab plus platinum-based chemotherapy in recurrent or metastatic head and neck cancer

Annals of Oncology (2010)

Contributed translational analyses supporting cetuximab combination utility in HNSCC, informing EXTREME regimen adoption as standard first-line treatment.

🏆Awards & Recognition 奖项与荣誉

🏆German Cancer Society (DKG) Leadership Award
🏆Arbeitsgemeinschaft Dermatologische Onkologie (ADO) Merit Award
🏆ESMO Faculty Recognition for Melanoma
🏆Berlin Cancer Society Distinguished Researcher Prize

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 乌尔里希·凯尔霍尔茨 的研究动态

Follow Ulrich Keilholz's research updates

留下邮箱,当我们发布与 Ulrich Keilholz(Charité – Universitätsmedizin Berlin)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment